Doctors Recommend A New Treatment For Cancer

Doctors Recommend A New Treatment For Cancer.
The remedy Arimidex reduces the imperil of developing breast cancer by more than 50 percent among postmenopausal women at tainted risk for the disease, according to a new study Dec 2013. The finding, scheduled for appearance Thursday at the San Antonio Breast Cancer Symposium in Texas, adds count that Arimidex (anastrozole) might be a valuable new preventive option for some women. The study will also be published in the journal The Lancet.

So "Two other antihormone therapies, tamoxifen and raloxifene, are in use by some women to prevent breast cancer, but these drugs are not as effective and can have adverse side effects, which determine their use," study lead author Jack Cuzick said in a new release from the American Association for Cancer Research. "Hopefully, our findings will outstrip to an alternative prevention therapy with fewer string effects for postmenopausal women at high risk for developing breast cancer," said Cuzick, climax of the Cancer Research UK Centre for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.

About 80 percent of US bust cancer patients have tumors with expensive levels of hormone receptors, and these tumors are fueled by the hormone estrogen. Arimidex prevents the body from making estrogen and is therefore cast-off to treat postmenopausal women with hormone receptor-positive titty cancer. The study included more than 3800 postmenopausal women at increased endanger for breast cancer due to having two or more blood relatives with breast cancer, having a innate or sister who developed breast cancer before age 50, or having a nourish or sister who had breast cancer in both breasts.

About half the women took Arimidex for five years while the others took a placebo, or dunce drug. Those who took the drug were 53 percent less probable to develop breast cancer than those who took the placebo. Side effects among the women taking the narcotize included hot flashes and small increases in muscle aches and pains. The work received funding from the drug companies AstraZeneca and Sanofi-Aventis, and Cuzick is on the speaker's subsection for AstraZeneca.

Two breast cancer experts in the United States expressed optimism about the new findings. "This is very rip-roaring information," said Dr Amy Tiersten, associate professor of panacea at the Icahn School of Medicine at Mount Sinai, in New York City. She said that although tamoxifen and raloxifene can also share a woman's odds for breast cancer, "these medications can somewhat increase the risk of blood clots and uterine cancer.

It is great to have a less toxic option to offer patients in the preventative arena," she said of Arimidex. Dr Stephanie Bernik, paramount of surgical oncology at Lenox Hill Hospital in New York City, agreed. "It is with unfenced arms that we can combine Arimidex to the medications that can be offered to postmenopausal women that are at high risk of developing mamma cancer.

So "Because Arimidex has less side effects, more women are likely to undergo preventive treatment. This will in the final analysis help decrease the incidence of breast cancer in women in this category. We are planning to sustain following the study participants for at least 10 years, and hopefully much longer," turn over author Cuzick said premature ejaculation delivered tomorrow. "We want to determine if Arimidex has a continued impact on cancer number even after stopping treatment, if it reduces deaths from breast cancer, and to ensure that there are no long-term adverse team effects".